Literature DB >> 1974295

Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs.

D L Lancaster1, R A Adio, K K Tai, O O Simooya, G D Broadhead, G T Tucker, M S Lennard.   

Abstract

The ability of a series of antimalarial drugs to impair the metabolism of metoprolol in rat and man has been examined. Chloroquine was a potent inhibitor in rat liver microsomes (Ki value for metoprolol alpha-hydroxylation = 0.18 microM and for O-demethylation = 0.36 microM). The other antimalarial drugs also inhibited metoprolol oxidation. Quinine was similar to chloroquine in potency, while quinidine, primaquine and mefloquine were slightly less potent. Chloroquine also inhibited metoprolol oxidation in human liver microsomes, although it was about two orders of magnitude less potent than in the rat and the extent of impairment varied greatly between individual livers. Intraperitoneal administration of chloroquine to anaesthetized rats decreased the clearance of metoprolol (40 mg tartrate salt kg-1 i.p.) to 54, 34, 20 and 26% of the control value at doses of 2.5, 4.0, 25 and 40 mg kg-1, respectively. We conclude that antimalarial treatment might have contributed to a previously reported difference in the metabolic pattern of metoprolol between Caucasians and Nigerians.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974295     DOI: 10.1111/j.2042-7158.1990.tb05405.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  12 in total

1.  Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.

Authors:  Sunetra Ray; Peter B Madrid; Paul Catz; Susanna E LeValley; Michael J Furniss; Linda L Rausch; R Kiplin Guy; Joseph L DeRisi; Lalitha V Iyer; Carol E Green; Jon C Mirsalis
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

Review 2.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

3.  Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

Authors:  O O Simooya; G Sijumbil; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

4.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 5.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

6.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

Authors:  V Spaldin; S Madden; W F Pool; T F Woolf; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

7.  Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.

Authors:  A Adedoyin; R F Frye; K Mauro; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

8.  Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.

Authors:  C M Masimirembwa; J A Hasler; I Johansson
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

Authors:  Slobodan Rendic; Frederick Peter Guengerich
Journal:  Curr Drug Metab       Date:  2020       Impact factor: 3.731

10.  Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report.

Authors:  Tuan M Tran; Joseph Browning; Mary L Dell
Journal:  Malar J       Date:  2006-08-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.